Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015912 · ClinicalTrials.gov registry record · Phase 2
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00015912: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00015912 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00015912, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere with the growth of cancer cells. Combining thalidomide with interferon alfa may kill more tumor cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL recombinant interferon alfa
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015912
The ClinicalTrials.gov registry entry for NCT00015912 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00015912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00015912 about?
NCT00015912 is a clinical study titled "Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere with the growth of cancer ...
What is the current status of trial NCT00015912?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2001-07.
What interventions are being tested in trial NCT00015912?
The interventions under investigation include: laboratory biomarker analysis (OTHER), recombinant interferon alfa (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00015912?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.